Core Insights - The economic data for Shenzhen Pingshan District in 2025 shows a GDP growth of 10.5%, nearly double the city's growth rate, with industrial added value increasing by 15.9% and retail sales growing by 10.2% [1][2] - Pingshan has established a modern industrial system centered on advanced manufacturing, which is becoming the core engine for economic growth in the region [1][2] Industrial Growth - Pingshan's industrial added value increased by 15.9% in 2025, highlighting the resilience and growth potential of the region's economy, particularly in advanced manufacturing [1][2] - The district has developed a "6+3" industrial cluster led by "vehicle, medicine, chip, and intelligence," forming a complete industrial ecosystem [2] - BYD, a leading company in the new energy vehicle sector, has entered the ranks of the world's top 100 companies and is the global sales champion for pure electric vehicles [2] - The biopharmaceutical sector has over 1,300 companies, with a record $1.64 billion collaboration agreement in CAR-T therapy [2] - Pingshan is a hub for silicon-based semiconductors, with chip manufacturing capacity exceeding 50% of the city's total, and a 23% increase in annual output value in 2025 [2] Innovation Investment - The R&D intensity in Pingshan reached 11.8% in 2024, with 98.39% of the investment coming from enterprises, significantly exceeding national averages [3] - The district has established high-level innovation platforms, creating a complete innovation ecosystem from basic research to industrialization [4] Consumer Market Dynamics - Retail sales in Pingshan grew by 10.2%, with a 28.5% increase in retail goods sales, supported by a local "trade-in" subsidy policy [6] - The district has seen the addition of flagship stores and new commercial complexes, enhancing consumer engagement and diversifying consumption scenarios [6] - Cultural and tourism consumption has emerged as a new growth point, with over 40 unique tourism routes launched [6] Foreign Trade and Investment - Pingshan's foreign trade saw a 13.7% increase, driven by the export of high-value goods such as new energy vehicles and biopharmaceuticals [6][7] - Fixed asset investment during the 14th Five-Year Plan period exceeded the total of the previous three plans, with industrial investment making up 54% of total fixed asset investment [7]

Core Viewpoint - The Shanghai government report for 2026 indicates a GDP growth target of around 5% for the city, maintaining the same target set for 2025, reflecting a shift towards high-quality development and a focus on building a self-reliant industrial and supply chain system [2][6]. Economic Performance - In 2025, Shanghai's GDP reached 5.67 trillion yuan, growing by 5.4%, which was better than expected [1]. - The total retail sales of consumer goods in Shanghai grew by 4.6% in 2025, surpassing the national average growth rate of 3.7% and reversing a decline of 3.1% in 2024 [1][6]. Consumption and Retail Strategies - Shanghai implemented various initiatives to boost consumption in 2025, including the issuance of "Le Shanghai" service consumption vouchers and the promotion of night economy and cultural tourism events [5][7]. - The number of tax refund stores for outbound tourists increased to 1,837, a growth of 136%, contributing significantly to the retail sales growth [6]. Industrial Development - The three leading industries in Shanghai—integrated circuits, biomedicine, and artificial intelligence—surpassed a combined scale of 2 trillion yuan in 2025 [8]. - Shanghai's focus on high-end industrial structure is evident, with significant advancements in strategic emerging industries [2][8]. Innovation and R&D - In 2025, Shanghai's total R&D expenditure was approximately 4.5% of its GDP, with a target of increasing this to 4.6% in 2026 [9]. - The city aims to enhance its innovation capabilities by establishing high-quality incubators and concept verification platforms, and by promoting the integration of technology and industry [8][9].

Core Insights - The article highlights the rapid development and supportive ecosystem for talent and innovation in Changchun New Area, showcasing successful projects and investments in high-tech sectors [2][11]. Group 1: Talent Attraction and Support - In 2025, Changchun New Area secured a competitive advantage in talent acquisition by integrating innovation, industry, funding, and talent chains [4]. - The area has established a "励志奖学金" (Inspiration Scholarship) and developed 200,000 square meters of talent apartments to create a conducive environment for innovation and entrepreneurship [4][14]. - The total number of industrial talents in the region reached 150,000, with over 8,800 new urban jobs created in a year, attracting 19,800 young graduates [15]. Group 2: Innovation and Research Development - Changchun New Area has gathered 103 intellectual property service institutions, accounting for 48.27% of the city's effective invention patents, with a high density of valuable patents ranking among the top in the country [15]. - The region has incubated 40 enterprises through the Jilin Provincial Science and Technology Innovation Research Institute, generating revenues of 900 million yuan [6][13]. - The establishment of 12 cooperation teams between universities and local governments has led to the identification of 315 technology achievements, with several high-profile projects successfully landing in the area [6][14]. Group 3: Entrepreneurial Ecosystem - The "千帆竞发" (Thousand Sails Competing) innovation incubation platform has established 59 incubation carriers, housing over 1,360 enterprises and creating more than 30,000 job opportunities [6][14]. - The Northeast's first operational new quality productivity development promotion center has organized 118 various events, enhancing the service capabilities for innovation and entrepreneurship [6][14]. - The area has successfully attracted 20 high-quality overseas innovation projects, including advanced technologies from international universities [14].

2026年上海市政府工作报告指出，2025年上海集成电路、生物医药、人工智能三大先导产业规模历史性 突破2万亿元，成为驱动城市高质量发展的核心引擎。正在进行的上海两会期间，多位政协委员在接受 第一财经记者采访时表示，该成绩标志上海新质生产力培育取得重大突破，为构建现代化产业体系筑牢 根基。 2026年上海市政府工作报告指出，2025年上海集成电路、生物医药、人工智能三大先导产业规模历史性 突破2万亿元，成为驱动城市高质量发展的核心引擎。正在进行的上海两会期间，多位政协委员在接受 第一财经记者采访时表示，该成绩标志上海新质生产力培育取得重大突破，为构建现代化产业体系筑牢 根基。 ...

Group 1 - The core viewpoint of the article is that Sichuan Shuangma has expanded its business by acquiring Shenzhen Jianyuan, a biopharmaceutical company, enhancing its operational vitality and future development prospects [1] - The company aims to solidify its investment sectors while continuously promoting the in-depth development of its biopharmaceutical business [1] - Sichuan Shuangma is focused on improving operational efficiency to create more value and returns for its shareholders [1]

Economic Performance - Shanghai's GDP reached 5.67 trillion yuan, growing by 5.4% year-on-year, exceeding expectations and marking a steady rise from being the first "5 trillion city" in the country [1] - The total import and export volume reached 4.51 trillion yuan, with a growth of 5.6%, and exports increased by 10.8% [1] Industry Development - The three leading industries, integrated circuits, biomedicine, and artificial intelligence, surpassed a scale of 2 trillion yuan, indicating continuous optimization of the economic structure [1] Employment and Income - The per capita disposable income of residents reached 92,000 yuan, an increase of 4.1%, while the average urban unemployment rate was 4.2% [3] Future Goals and Plans - The GDP growth target for this year is set at around 5%, with local general public budget revenue expected to grow by 2% [5] - The report emphasizes the need to boost domestic demand and consumer spending, with plans to create 20 new integrated service consumption scenarios [5] Social Welfare Initiatives - Plans include the renovation of 200,000 square meters of old housing, the addition of 2,000 cognitive care beds, and the establishment of 200 local elderly care service stations [7] - A new round of child-friendly city initiatives and improvements in school meal quality are also set to be implemented [7] Long-term Vision - By 2035, Shanghai aims to double its per capita regional GDP compared to 2020, striving to become a globally influential modern socialist metropolis [11] - The current period is seen as a critical phase for transformation and upgrading, with the success of this year influencing future developments [9]

Core Viewpoint - The emergence of Bo Luo County as Guangdong's first "billion county" signifies a shift in the province's development model, placing greater emphasis on county-level economic growth alongside urban development [2][3]. Economic Milestones - Bo Luo County's GDP is projected to exceed 100 billion yuan by 2025, marking a significant milestone for Guangdong, which has historically lacked representation in the "billion county club" [2]. - The number of "billion counties" in China has increased to 62 by 2024, with notable examples from Jiangsu Province, where some counties have GDPs exceeding 500 billion yuan [2]. County Economic Dynamics - The lack of "billion counties" in Guangdong has been attributed to a focus on urban centers like Shenzhen and Guangzhou, leading to a disparity in county-level economic development [2][6]. - The administrative evolution in the Pearl River Delta has resulted in the transformation of many economically strong counties into districts, impacting the county economic landscape [5][6]. Development Strategies - Bo Luo County has shifted from a fragmented industrial approach to a systematic development strategy, focusing on key industries and establishing industrial parks to enhance competitiveness [10][13]. - The county has successfully developed eight industrial clusters, including new-generation electronic information and intelligent equipment manufacturing, aligning with national strategic directions [10][13]. Regional Collaboration - Bo Luo County's integration with Huizhou's urban area has facilitated infrastructure connectivity and collaborative development, enhancing its economic dynamism [10][13]. - The "Hundred Counties, Thousand Towns, and Ten Thousand Villages High-Quality Development Project" aims to address urban-rural disparities and promote balanced regional development [6][12]. Future Prospects - Other counties in Guangdong, such as Hui Dong and Zhaoqing, are on track to achieve "billion county" status, indicating a potential trend in county-level economic growth [7][14]. - The experiences of Jiangsu and Zhejiang provinces in county economic development may provide valuable insights for Guangdong in cultivating more competitive counties [14][15].

新华社上海2月3日电（记者王永前、杨有宗）5年经济增量超1.5万亿元，上海综合经济实力再攀新 高峰。"十四五"时期，上海市生产总值从4.16万亿元增加到5.67万亿元，跻身全球城市前五位，交出了 一份分量十足的发展答卷。 这是记者从3日开幕的上海市第十六届人民代表大会第四次会议上获悉的。 "'十四五'时期，上海发展历程极不寻常、极不平凡。"上海市市长龚正表示，经过五年发展，上海 人均地区生产总值达到3.2万美元，全员劳动生产率提高到42万元/人以上，单位生产总值能耗累计下降 14%。 上海一直以来是外商最青睐的投资首选地之一。前不久，米其林上海工厂改扩建二期工程宣告正式 投入生产，到2026年底达产100万条，工厂整体年产能将由850万条提升至950万条。 "十四五"期间，上海实际使用外资累计超过1000亿美元，认定跨国公司地区总部从771家增加至 1076家。 1.5万亿元增量，勾勒出人民美好生活新图景。过去五年，上海历史性完成中心城区成片、零星二 级旧里以下房屋改造，困扰上海多年的"拎马桶"问题得到总体解决。 面向未来，龚正表示，在"十五五"基础上再奋斗五年，上海"五个中心"功能将全面升级，人均地区 生产 ...

Group 1 - The company has changed its English name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited" and its Chinese name from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," effective from December 30, 2025 [1] - The change in company name has been approved by shareholders at a special meeting and registered with the Cayman Islands Registrar of Companies [1] - The Hong Kong Companies Registry has confirmed the new names have been registered under the Companies Ordinance [1] Group 2 - The company's stock trading name on the Hong Kong Stock Exchange will change from "GENOR" to "EDDING GENOR," and the Chinese stock name will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [2] - The company's stock code on the Hong Kong Stock Exchange will remain "6998" [2] - The name changes aim to better reflect the expanded business of the group following the completion of a merger and the relationship with the controlling shareholder [2]

Core Viewpoint - Federal Pharmaceutical's subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received clinical trial approval for its innovative drug UBT251 injection for the treatment of moderate to severe obstructive sleep apnea (OSA) in China, indicating a significant advancement in addressing unmet clinical needs in this area [1] Group 1 - UBT251 injection is a multi-target peptide receptor agonist that acts on GLP-1, GIP, and GCG receptors to lower blood sugar and inhibit weight gain, positioning the company favorably in the obesity treatment market [1] - The drug is expected to fill a substantial gap in the treatment of OSA, which has a high unmet clinical demand [1] - UBT251 is also undergoing Phase II clinical trials in China for indications including overweight or obesity, type 2 diabetes, metabolic-associated fatty liver disease, and chronic kidney disease [1] Group 2 - As the first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist in China, UBT251 enhances the company's position in the research and development of this class of drugs [1] - The company aims to continue its focus on new product development to strengthen its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]